{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:27:25Z","timestamp":1784003245846,"version":"3.55.0"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6460,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1995,7]]},"abstract":"<jats:p>Iloperidone (HP 873) is a D<jats:sub>2<\/jats:sub> and 5\u2010HT<jats:sub>2<\/jats:sub> receptor\u2010antagonist that is under development as a potential atypical antipsychotic agent. Two studies on iloperidone evaluated its safety and tolerability, made a preliminary pharmacokinetic assessment of single 3\u2010 and 5\u2010mg doses, and determined the effect of food on its tolerability and pharmacokinetics in healthy volunteers after single 3\u2010mg doses. Iloperidone was well absorbed orally in fasted subjects. The C<jats:sub>max<\/jats:sub> occurred approximately 2 to 3 hours after administration of a single 3\u2010 or 5\u2010mg dose. The pharmacokinetic parameters increased with the dose between 3 and 5 mg (from 2.2 to 5.2 ng\/mL for C<jats:sub>max<\/jats:sub>, and 16 to 50 ng\/mL\u2022h for AUC). Iloperidone was eliminated slowly, with a mean t<jats:sub>1\/2<\/jats:sub> of 13.5 to 14.0 hours. Coadministration with food did not significantly affect AUC, t<jats:sub>max<\/jats:sub>, or C<jats:sub>max<\/jats:sub>. These results indicate that the rate of iloperidone's absorption is decreased, but the overall bioavailability is unchanged, when the drug is taken with food. Orthostatic hypotension, dizziness, and somnolence were the most commonly reported adverse events. Coadministration of food reduced the incidence and severity of these events.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1995.tb04112.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:25:28Z","timestamp":1362770728000},"page":"713-720","source":"Crossref","is-referenced-by-count":37,"title":["Safety, Tolerability, and Effect of Food on the Pharmacokinetics of Iloperidone (HP 873), a Potential Atypical Antipsychotic"],"prefix":"10.1002","volume":"35","author":[{"given":"Stephen M.","family":"Sainati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Grasing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Brecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"249","article-title":"The neurochemical profile of HP 873, a potential atypical antipsychotic with D2\/5\u2010HT2 receptor antagonist activity (abstract)","volume":"16","author":"Wilmot CA","year":"1990","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_3_2","first-page":"249","article-title":"The in vivo pharmacology of the novel antipsychotic HP 873 (abstract)","volume":"16","author":"Szewczak MR","year":"1990","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_4_2","first-page":"MEDI\u201087","article-title":"Antipsychotic activity of 1H\u2010indazol\u20103\u2010ylpiperidine and piperazine analogs of the potential atypical antipsychotic HP 873 (abstract)","volume":"203","author":"Strupczewski JT","year":"1992","journal-title":"Am Chem Soc Abstr"},{"key":"e_1_2_1_5_2","first-page":"MEDI\u20102","article-title":"HP 873: a D2\/5 HT2 antagonist with the profile of a potential atypical antipsychotic (abstract)","volume":"201","author":"Strupczewski JT","year":"1990","journal-title":"Am Chem Soc Abstr"},{"key":"e_1_2_1_6_2","first-page":"MEDI\u2010130","article-title":"Synthesis and evaluation of N\u2010(aryloxyalkyl) heteroaryltropanes as potential antipsychotic agents (abstract)","volume":"202","author":"Kurys BE","year":"1991","journal-title":"Am Chem Soc Abstr"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00653-8"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(93)90079-9"},{"key":"e_1_2_1_9_2","first-page":"177","article-title":"HP 873, a potential atypical antipsychotic agent: pharmacokinetics in rats and dogs","volume":"33","author":"Chesson SM","year":"1991","journal-title":"Pharmacologist"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01068419"},{"key":"e_1_2_1_11_2","article-title":"Pharmacokinetics of risperidone in chronic schizophrenic patients","author":"Borison RL","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_12_2","first-page":"S80","article-title":"Pharmacological profile of risperidone","volume":"38","author":"Ereshefsky L","year":"1993","journal-title":"Can J Psychiatry"},{"key":"e_1_2_1_13_2","volume-title":"The binding of 14C\u2010HP873 to rat, dog and human plasma proteins","author":"Hartley TE","year":"1993"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040050-00007"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6047.1293"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1995.tb04112.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1995.tb04112.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T01:59:51Z","timestamp":1698285591000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1995.tb04112.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1995,7]]}},"alternative-id":["10.1002\/j.1552-4604.1995.tb04112.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04112.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,7]]}}}